ClinicalTrials.gg
RecruitingNCT06885281Updated Aug 21, 2026

A Study of ZL-1310 in Participants With Selected Solid Tumors

A Phase 1/2 interventional study of ZL-1310 in Solid Tumors, sponsored by Zai Lab (Shanghai) Co., Ltd.. Recruiting at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
166
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

Read the detailed description

This is an open-label, multiple-center, phase 1b/2 study of ZL-1310 in selected solid tumors. ZL-1310 will be administered intravenously at 1.6 mg/kg every 21 days. Primary objectives include safety evaluation and confirmed objective response rate by blinded independent central review

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Zai Lab (Shanghai) Co., Ltd. is the lead sponsor of 25 studies on the registry; 8 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Adult men and women ≥18 years of age
  • Participants must have confirmed, locally advanced or NeuroEndocrine Carcionomas (NEC)
  • Participants must be willing to undergo a tumor or must provide archived tumor tissue sample
  • Participants must have at least one measurable target lesion as defined by v1.1
  • (ECOG) performance status of 0 or 1
  • ≥ 3 months

Exclusion criteria

Exclusion Criteria:

  • Participants with another known that is progressing or requires active treatment within the last 2 years
  • Clinically active central nervous system (CNS)
  • Participants with
  • Participants who have received any ADC with a payload of topoisomerase I inhibitor (e.g., exatecan derivative)or had received topoisomerase I inhibitor (e.g., irinotecan) as the immediate prior therapy that the participant had progressed from.
  • Treatment with any systemic anti-cancer treatment or other products/device within 3 weeks before the first dose of study treatment
  • Non-palliative radiotherapy within 2 weeks to non-thoracic area or within 4 weeks to the thoracic area prior to first dose of study treatment or a history of radiation pneumonitis
  • Major surgery within 4 weeks of the first dose of study treatment
  • to any ingredient of the study treatment
  • Out of range value (as defined in protocol) within 10 days prior to the first dose of study treatment
  • Impaired cardiac function or cardiac disease within the last 3 months before administration of the first dose of the study treatment
  • Lung-specific intercurrent clinically significant illnesses and any , connective tissue, or inflammatory disorders including but not limited to pneumonitis
  • Has a history of (noninfectious) ILD/pneumonitis that required , has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening
  • Pregnant or nursing (lactating) women
  • Participants who have been on concomitant strong or CYP2D6 inhibitors within 14 days or 5 half-lives before the first dose of study treatment, whichever is longer
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
166 participants (estimated)

Study arms

  • Experimental
    Single Arm

    ZL-1310 as a single agent

    Drug: ZL-1310

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse-Events in Phase 1b

    Number of subjects with treatment-emergent adverse events (TEAEs)

    Time frame: up to 36 months

  2. Incidence of Serious Adverse Events in Phase 1b

    Number of subjects with serious adverse events (SAEs)

    Time frame: up to 36 months

  3. Evaluate antitumor activity of ZL-1310 as a single agent in Phase 2

    Confirmed objective response rate (ORR) determined by blinded independent central review (BICR) in Phase 2

    Time frame: up to 36 months

Secondary outcomes

  1. Evaluate preliminary antitumor activity of ZL-1310 as a single agent in Phase 1b

    1. BICR-determined confirmed ORR in all cohorts 2. Investigator-determined confirmed ORR in all cohorts 3. BICR-determined 6-months progression-free survival (PFS6) rate in Cohort 3 4. Investigator-determined PFS6-rate in Cohort 3

    Time frame: up to 36 months

  2. Evaluate durability of response in Phase 1b

    1\. BICR- and investigator-determined duration of response (DOR) in Phase 1b

    Time frame: up to 36 months

  3. Evaluate preliminary antitumor activity of ZL-1310 as a single agent in Phase 2

    Investigator-determined confirmed ORR in Phase 2

    Time frame: up to 36 months

  4. Evaluate durability of response in Phase 2

    1\. BICR- and investigator-determined duration of DOR in Phase 2

    Time frame: up to 36 months

  5. Incidence of Treatment Emergent Adverse-Events in Phase 2

    Number of subjects with treatment-emergent adverse events (TEAEs)

    Time frame: up to 36 months

  6. Incidence of Serious Adverse Events in Phase 2

    Number of subjects with serious adverse events (SAEs)

    Time frame: up to 36 months

  7. Pharmacokinetics (PK): Time to maximum concentration (Tmax) of Total Antibody in all phases

    Time to maximum concentration (Tmax) is a pharmacokinetic parameter that refers to the time it takes for a drug or substance to reach its highest concentration in the bloodstream or a specific body compartment after administration

    Time frame: up to 36 months

  8. Pharmacokinetics (PK): maximum concentration (Cmax) of Total Antibody in all phases

    Maximum concentration (Cmax) is a key pharmacokinetic parameter. It represents the highest concentration of a drug or substance that is achieved in the bloodstream or a specific biological fluid or tissue after administration

    Time frame: up to 36 months

  9. Pharmacokinetics (PK): area under the concentration-time curve (AUC) of Total Antibody in all phases

    Area under the concentration-time curve (AUC) is a pharmacokinetic parameter that quantitatively describes the total exposure of a drug in the body over a specific period of time

    Time frame: up to 36 months

  10. Pharmacokinetics (PK): apparent clearance (CL) of Total Antibody in all phases

    Apparent clearance (CL) is a pharmacokinetic parameter that describes the rate at which a drug is removed from the body relative to the drug's concentration in the bloodstream or a specific body fluid

    Time frame: up to 36 months

  11. Pharmacokinetics (PK): terminal elimination half-life (T1/2) of Total Antibody in all phases

    Terminal elimination half-life (T1/2) is a pharmacokinetic parameter that characterizes the time it takes for the concentration of a drug in the body to decrease by half during the terminal phase of drug elimination

    Time frame: up to 36 months

  12. Pharmacokinetics (PK): time to maximum concentration (Tmax) of Unconjugated payloads in all phases

    Time to maximum concentration (Tmax) is a pharmacokinetic parameter that refers to the time it takes for a drug or substance to reach its highest concentration in the bloodstream or a specific body compartment after administration

    Time frame: up to 36 months

  13. Pharmacokinetics (PK): maximum concentration (Cmax) of Unconjugated payloads in all phases

    Maximum concentration (Cmax) is a key pharmacokinetic parameter. It represents the highest concentration of a drug or substance that is achieved in the bloodstream or a specific biological fluid or tissue after administration

    Time frame: up to 36 months

  14. Pharmacokinetics (PK): area under the concentration-time curve (AUC) of Unconjugated payloads in all phases

    The area under the concentration - time curve (AUC) is a pharmacokinetic parameter that quantitatively describes the total exposure of a drug in the body over a specific period of time

    Time frame: up to 36 months

  15. Pharmacokinetics (PK): apparent clearance (CL) of Unconjugated payloads in all phases

    Apparent clearance (CL) is a pharmacokinetic parameter that describes the rate at which a drug is removed from the body relative to the drug's concentration in the bloodstream or a specific body fluid

    Time frame: up to 36 months

  16. Pharmacokinetics (PK): terminal elimination half-life (T1/2) of unconjugated payloads in all phases

    Terminal elimination half - life (T1/2) is a pharmacokinetic parameter that characterizes the time it takes for the concentration of a drug in the body to decrease by half during the terminal phase of drug elimination

    Time frame: up to 36 months

  17. Assess immunogenicity of ZL-1310 in all phases

    Incidence of anti-drug antibodies (ADAs) to ZL-1310 in all phases

    Time frame: up to 36 months

  18. Evaluate stability and control of disease in all phases

    BICR- and investigator-determined disease control rate (DCR) in all phases

    Time frame: up to 36 months

  19. Evaluate progression-free survival (PFS) in all phases

    BICR- and investigator-determined PFS in all phases

    Time frame: up to 36 months

  20. Evaluate survival in all phases

    Overall survival (OS) in all phases

    Time frame: up to 36 months

07

Study locations

23 of 23 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Aug 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Mar 20, 2025
StartActual
May 12, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Apr 2028
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06885281
Collaborators
Zai Lab (US) LLC
Responsible party
Sponsor
First posted
Mar 20, 2025
Start date
May 12, 2025
Primary completion
Aug 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Aug 21, 2026

Study contacts

ZaiLab_1310-002_StudyTeam
Contact
Zailab_1310-002_StudyTeam@zailaboratory.com
6503601601

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zocilurtatug Pelitecan

Start the discussion